WO2015182140A1 - 足場依存性細胞の培地及び培養方法、並びに幹細胞及び/又は幹細胞から誘導された分化細胞を含む細胞組成物及びその製造方法 - Google Patents
足場依存性細胞の培地及び培養方法、並びに幹細胞及び/又は幹細胞から誘導された分化細胞を含む細胞組成物及びその製造方法 Download PDFInfo
- Publication number
- WO2015182140A1 WO2015182140A1 PCT/JP2015/002694 JP2015002694W WO2015182140A1 WO 2015182140 A1 WO2015182140 A1 WO 2015182140A1 JP 2015002694 W JP2015002694 W JP 2015002694W WO 2015182140 A1 WO2015182140 A1 WO 2015182140A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- stem cells
- medium
- cell
- anchorage
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Definitions
- the present invention relates to a medium and a culture method for anchorage-dependent cells, a cell composition containing stem cells and / or differentiated cells derived from stem cells, and a method for producing the same. More specifically, the present invention relates to a medium for culturing anchorage-dependent cells without using a scaffold, and a method for producing stem cells and the like using the medium.
- scaffolds The same applies to the culture of stem cells such as ES cells (embryonic stem cells) and iPS cells (induced pluripotent stem cells), and it is known that it is difficult to grow cells in the absence of scaffolds or feeder cells. Yes.
- stem cells such as ES cells (embryonic stem cells) and iPS cells (induced pluripotent stem cells), and it is known that it is difficult to grow cells in the absence of scaffolds or feeder cells. Yes.
- ES cells embryonic stem cells
- iPS cells induced pluripotent stem cells
- Non-patent Document 1 Matrigel and recombinant protein
- Non-patent Document 2 and 3 scaffolds using polymers such as polymers have been developed (Non-Patent Documents 2 and 3), but they are still very expensive and may not be suitable depending on the cell line.
- Milk fat globule-EGF factor 8 (MFG-E8) is a racodherin homolog in humans and is a membrane-bound glycoprotein found in breast milk and breast epithelial cells (see Non-patent Document 1).
- Non-Patent Document 4 describes that administration of MFG-E8 can be effective in the treatment of sepsis and ischemia-reperfusion injury.
- Non-Patent Document 5 describes that MFG-E8 secreted from activated macrophages binds to apoptotic cells and induces phagocytic phagocytosis. So far, it has not been known to add MFG-E8 to a medium for animal cells or to culture anchorage-dependent cells or iPS cells in the presence of MFG-E8.
- the main object of the present invention is to provide a technique capable of culturing scaffold-dependent cells without using a scaffold.
- MFG-E8 promotes adhesion of anchorage-dependent cells in the absence of the scaffold, cell survival and proliferation (colony formation), and further when the anchorage-dependent cells are stem cells. We have found that differentiation is possible.
- the present invention provides the following [1] to [25].
- An adhesion promoter for anchorage-dependent cells comprising MFG-E8 or a fragment of the protein.
- a method for culturing an anchorage-dependent cell comprising a step of culturing an anchorage-dependent cell in the absence of the anchorage in a medium containing MFG-E8 or a fragment of the protein.
- the culture method according to [7], wherein the anchorage-dependent cells are stem cells.
- the stem cells are embryonic stem cells, inducible pluripotent stem cells, or mesenchymal stem cells.
- the culture method according to any one of [7] to [9], wherein the anchorage-dependent cells are derived from a human.
- the medium is a serum-free medium.
- a method for producing a cell composition containing stem cells comprising culturing stem cells in the absence of a scaffold in a medium containing MFG-E8 or a fragment of the protein.
- stem cells are embryonic stem cells, inducible pluripotent stem cells, or mesenchymal stem cells.
- the stem cell is derived from a human.
- [17] A method for producing a cell composition containing differentiated cells from stem cells, comprising a step of inducing stem cell differentiation in the absence of a scaffold in a medium containing MFG-E8 or a fragment of the protein.
- the production method of [17], wherein the stem cells are embryonic stem cells, inducible pluripotent stem cells, or mesenchymal stem cells.
- a cell composition comprising stem cells and / or differentiated cells derived from stem cells cultured in a medium containing MFG-E8 or a fragment of the protein in the absence of a scaffold.
- the present invention provides a technique capable of culturing anchorage-dependent cells without using a scaffold.
- Example 1 which is a figure which shows the result of having evaluated the effect of MFG-E8 when a scaffold dependence cell was cultured in the absence of a scaffold using a human iPS cell.
- the plate with no scaffold coated was cultured for 4 days in the presence or absence of MFG-E8, and the area of the grown colonies was measured. It is a figure which shows the result of having evaluated the effect of MFG-E8 by changing the addition density
- the scaffold-dependent cell culture medium according to the present invention is characterized in that it contains MFG-E8 (Milk fat globule-EGF factor 8) or a fragment of the protein.
- the amino acid sequence of human MFG-E8 is shown in SEQ ID NO: 1 (GenBank Accession No. Q08431-1 http://www.uniprot.org/uniprot/Q08431).
- the amino acid sequence of human MFG-E8 may be GenBank Accession No. Q08431-2 or No Q08431-3 (http://www.uniprot.org/uniprot/Q08431).
- SEQ ID NO: 1 the first to 23rd amino acid sequences are secretory signal sequences.
- MFG-E8 is also referred to as lactadherin, medin, secreted EGF repeat and discoidin domains-containing protein 1 (SED1).
- the MFG-E8 used in the medium according to the present invention is not limited to the human MFG-E8 represented by SEQ ID NO: 1 and may have a non-human MFG-E8 (MFG) as long as it has an activity of promoting anchorage-dependent cell adhesion.
- MFG-E8 homologue may be from any animal, for example, rodents such as rats, mice, hamsters and guinea pigs, rabbit eyes such as rabbits, and ungulates such as pigs, cows, goats and sheep.
- mouse-derived MFG-E8 is described in PLoS ONE, 2012, 7, e36368 and PLoS ONE, 2011, 6, e27685.
- the MFG-E8 homolog used for the culture medium according to the present invention can be appropriately selected according to the origin of the anchorage-dependent cells to be cultured, and preferably MFG-E8 derived from the same animal as that of the anchorage-dependent cells to be cultured. A homolog is used. For example, when culturing human-derived cells, it is preferable to use human-derived MFG-E8.
- MFG-E8 used in the medium according to the present invention can be generated from the amino acid sequences of human MFG-E8 and MFG-E8 homologues as long as it has an activity of promoting adhesion of anchorage-dependent cells.
- Polypeptides fragments of MFG-E8 are also included.
- the length of the polypeptide is, for example, 21 to 100, preferably 101 to 200, more preferably 201 to 364 in terms of the number of amino acid residues.
- a specific example of a preferred fragment is a polypeptide (364 amino acid residues) consisting of the amino acid sequence from 24th to 387th of SEQ ID NO: 1.
- polypeptide is used interchangeably with “peptide” or “protein”.
- “MFG-E8 and fragments thereof” are also simply referred to as “MFG-E8”.
- MFG-E8 used in the medium according to the present invention has one or several amino acids in the amino acid sequences of human MFG-E8 and MFG-E8 homologues as long as it has an activity of promoting anchorage-dependent cell adhesion.
- an amino acid sequence obtained by adding a His tag sequence to an amino acid sequence (24th to 387th amino acid sequence) from which the signal sequence is deleted in SEQ ID NO: 1 can be mentioned.
- amino acid sequence in which one or several amino acids have been deleted, substituted, inserted or added can be deleted, substituted, inserted or added by a known mutant polypeptide production method such as site-directed mutagenesis. It means an amino acid sequence in which a certain number (preferably 10 or less, more preferably 7 or less, and still more preferably 5 or less) of amino acids are deleted, substituted, inserted or added. It is well known in the art that some amino acids in the amino acid sequence of a protein can be easily modified without significantly affecting the structure or function of the protein.
- amino acid sequence in which one or several amino acids are deleted, substituted, inserted or added is not limited to a sequence in which mutation is artificially introduced by a known mutant polypeptide production method. It may also be the amino acid sequence of a variant present in
- the MFG-E8 used in the medium according to the present invention may be a protein isolated or purified from nature, a recombinant protein or a synthetic protein, or may be chemically modified. Isolation of natural proteins, expression of recombinant proteins, protein synthesis, or purification of these proteins can be performed by a conventionally known technique.
- the composition of the medium according to the present invention may be the same as that conventionally used for culturing anchorage-dependent cells, except that it contains MFG-E8.
- Examples of such a medium include a medium used for culturing cells derived from animal tissues. Specifically, the following culture media can be mentioned.
- RPMI-1640 medium Eagle's MEM medium, Dulbecco's modified MEM medium, GMEM (Glasgow's MEM), ⁇ -MEM, 199 medium, IMDM medium, DMEM medium Hybridoma Serum free medium (Invitrogen Corporation), Chemically DefriedHybridFed medium (Invitrogen), Ham's Medium F-12, Ham's Medium F-10, Ham's Medium F12K, ATCC-CRCM30, DM-160, DM-201, BME, Fischer, McCoy's 5A, Leibovitz ' s L-15, RITC80-7, MCDB105, MCDB107, MCDB131, MCDB153, MCDB201, CTC109, NCTC135, Wayout's MB752 / 1, CMRL-1066, Williams' medium E, Brinster's BMOC-3 Medium, Essential8 Medium (Life Technologies), mTeSR1 (medium SR Technologies 8) ), StemS
- the medium according to the present invention can be prepared by adding MFG-E8 to these media in advance or during cell culture.
- concentration of MFG-E8 added to the medium is not particularly limited as long as it has an activity of promoting the adhesion of anchorage-dependent cells, and can be, for example, 1 ⁇ g / ml to 5 ⁇ g / ml.
- physiologically active substances and nutrient factors necessary for cell survival or proliferation can be added to the medium as needed. These additives may be added in advance to the medium, or may be added during cell culture.
- Nutritional factors include sugars, amino acids, vitamins, hydrolysates or lipids.
- examples of the sugar include neutral sugars such as glucose, mannose, or fructose; acidic sugars such as sialic acid; amino sugars; sugar alcohols, and the like.
- vitamins examples include d-biotin, D-pantothenic acid, choline, folic acid, myo-inositol, niacinamide, pyrodoxal, riboflavin, thiamine, cyanocobalamin or DL- ⁇ -tocopherol, and one or a combination of two or more Used.
- hydrolyzate examples include hydrolyzed soybeans, wheat, rice, peas, corn, cottonseed, yeast extract and the like.
- lipids include cholesterol, linoleic acid, and linolenic acid.
- an antibiotic such as kanamycin, streptomycin, penicillin or hygromycin may be added to the medium as necessary.
- an acidic substance such as sialic acid is added to the medium, it is desirable to adjust the pH of the medium to pH 5 to 9, preferably 6 to 8, which is a neutral range suitable for cell growth.
- the culture medium according to the present invention may be a serum-free medium, that is, a serum-free medium.
- the culture medium according to the present invention can contain serum, it is preferable not to contain serum from the viewpoint of preventing mixing of components derived from different animals.
- the serum-free medium means a medium containing no unadjusted or unpurified serum.
- the serum-free medium may contain a purified blood-derived component or animal tissue-derived component (for example, a growth factor).
- the medium according to the present invention may or may not contain a serum substitute as well as serum.
- Serum substitutes include, for example, albumin substitutes such as albumin, lipid-rich albumin and recombinant albumin, plant starch, dextran, protein hydrolysates, transferrin or other iron transporters, fatty acids, insulin, collagen precursors, trace amounts An element, 2-mercaptoethanol, 3′-thioglycerol, or an equivalent thereof may be used.
- Specific examples of serum substitutes include, for example, those prepared by the method described in WO 98/30679, commercially available Knockout Serum Replacement (KSR), Chemically-defined Lipid concentrated (Life Technologies max) and Gluta Life Technologies).
- “anchor-dependent cells” need to be attached for survival and / or proliferation, and are not viable and / or proliferatively inhibited in a non-adherent or floating state.
- the “scaffold-dependent cell” is not particularly limited as long as it is a cell derived from animal tissue that can adhere to and grow on a substrate of an incubator without a scaffold in the presence of MFG-E8.
- the “scaffold” widely includes proteins constituting the extracellular matrix in vivo and recombinant proteins or synthetic proteins thereof, modified products or partial polypeptides of these proteins, cell adhesion synthetic molecules, and the like.
- the Specific examples of scaffolds include collagen, gelatin, poly-L-lysine, poly-D-lysine, laminin, partial structures of laminin, fibronectin and mixtures thereof (eg, Matrigel) and lysed cell membrane preparations (Lancet, 2005, 365, p1636-1641). The following are listed as conventionally known scaffolds.
- Organic materials selected from the group of biopolymers consisting of collagen, gelatin, hyaluronic acid, proteoglycan, chitin, chitosan, chitosan derivatives, fibrin, dextran, agarose, calcium alginate, silk or combinations thereof, or aliphatic polyester, poly (Amino acid), poly (propylene fumarate), copoly (ether-ester), polyorthoester, polyalkylene oxalate, polyamide, polycarbonate, polycaprolactone, poly (iminocarbonate), polyorthoester, polyoxaester, polyamide ester , Polyoxaesters containing amine groups, polyanhydrides, polyphosphazenes, polyurethanes, hydroxybutyrate, dioxanone, or hydrogels such as polyacrylates Synthetic polymeric material selected from the group consisting of rate, polyvinyl alcohol, polyethylene glycol or polyethyleneimine, or any copolymer, blend or
- the species of anchorage-dependent cells to which the medium according to the present invention can be applied are not particularly limited, for example, rodents such as rats, mice, hamsters, guinea pigs, rabbits such as rabbits, pigs, cows, goats.
- the cells may be ungulates such as sheep, cats such as dogs and cats, primates such as humans, monkeys, rhesus monkeys, marmosets, orangutans and chimpanzees.
- anchorage-dependent cells to which the medium according to the present invention can be applied include CHO cells derived from Chinese hamster ovary, CHO-K1 (ATCC CCL-61), CHO / dhfr- (ATCC CRL-9096), Pro5 strain (ATCC CRL-1781), CHO-S (Invitrogen Cat # 11619); Baby hamster kidney-derived BHK cells; Human cervical cancer-derived HeLa cells; Mouse breast cancer-derived C-127 cells; Mouse fibroblasts NIH / 3T3, BALB3T3; VerotosS3 from African green monkey kidney; mouse cell line NS0 (ATCC CRL-1827), SP2 / 0 (ATCC CRL-1581); mouse myeloma cell line SP2 / 0-Ag14; rat myeloma cell line Y3 Ag1.2.3.
- CHO-K1 ATCC CCL-61
- CHO / dhfr- ATCC CRL-9096
- Pro5 strain ATCC
- anchorage-dependent cells that are stem cells include mesenchymal stem cells that differentiate into myoblasts, vascular endothelial cells, osteoblasts, adipocytes, myocytes, cardiomyocytes, chondrocytes, etc .; to neurons and glial cells Differentiating neural stem cells; hematopoietic stem cells or bone marrow stem cells that differentiate into leukocytes, erythrocytes, platelets, mast cells, dendritic cells, etc .; various tissues through the formation of pseudo-embryos (EB bodies) from the spheroid state Embryonic stem cells (embryonic stem cells: ES cells), inducible pluripotent stem cells (iPS cells), and embryonic embryos derived from primordial germ cells, which are known to proceed to differentiation / induction steps into cells Multipotent germlins isolated in the process of establishing GS cells from testicular tissue, germ (EG) cells em (mGS) cells, multipotent adult progenit
- anchorage-dependent cells that are stem cells
- C2C12 strain known to differentiate into myotubes
- 3T3-L1 strain known to differentiate into adipocytes
- Examples include striatum-derived mouse neural stem cells (MNSC); rat fetal midbrain-derived rat neural stem cells (RNSC); rat liver-derived cell line 3′-mRLh-2.
- the “stem cell” targeted by the present invention is not limited to the above, and refers to an immature cell having self-replication ability and differentiation / proliferation ability, and depending on the differentiation ability, a pluripotent stem cell (pluripotent stem cell). ), Multipotent stem cells, unipotent stem cells, and the like.
- a “stem cell” is generally defined as an undifferentiated cell having “self-renewal ability” capable of proliferating while maintaining an undifferentiated state and “differentiated pluripotency” capable of differentiating into all three germ layers.
- a pluripotent stem cell means a cell having an ability to differentiate into all tissues and cells constituting a living body.
- a multipotent stem cell means a cell having the ability to differentiate into multiple types of tissues and cells, although not all types.
- a unipotent stem cell means a cell having the ability to differentiate into a specific tissue or cell.
- pluripotent stem cells examples include the aforementioned ES cells or iPS cells.
- Stem cells established by culturing early embryos produced by nuclear transfer of somatic cell nuclei are also preferred as pluripotent stem cells (Nature, 1997, 385, 810; Science, 1998, 280, 1256; Nature). (Biotechnology, 1999, 17, 456; Nature, 1998, 394, 369; Nature Genetics, 1999, 22, 127; Proc. Natl. Acad. Sci. USA, 1999, 96, 14984; Nature Genetics, 2000, 24, 109) .
- Human ES cell lines are obtained from, for example, WA01 (H1) and WA09 (H9) from the WiCell Research Institute, and KhES-1, KhES-2 and KhES-3 from the Institute of Regenerative Medicine, Kyoto University (Kyoto, Japan). Is possible.
- iPS cells include cells that have acquired multipotency similar to ES cells obtained by introducing a plurality of genes (reprogramming factors) into somatic cells such as skin cells.
- iPS cells obtained by introducing Oct3 / 4 gene, Klf4 gene, C-Myc gene and Sox2 gene iPS cells obtained by introducing Oct3 / 4 gene, Klf4 gene and Sox2 gene (Nature Biotechnology, 2008) , 26, 101-106).
- genes included in the reprogramming factor include Oct3 / 4, Sox2, Sox1, Sox3, Sox15, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, ERas, ECAT15 -2, Tcl1, beta-catenin, Lin28b, Sall1, Sall4, Esrrb, Nr5a2, Tbx3 or Glis1 etc. are exemplified, and these reprogramming factors may be used alone or in combination.
- iPS cells can be obtained from predetermined institutions (RIKEN BioResource Center, Kyoto University, etc.).
- multipotent stem cells examples include somatic stem cells such as mesenchymal stem cells, hematopoietic stem cells, neural stem cells, bone marrow stem cells, and reproductive stem cells.
- the multipotent stem cell is preferably a mesenchymal stem cell, more preferably a bone marrow mesenchymal stem cell.
- the mesenchymal stem cell broadly means a group of stem cells or progenitor cells that can differentiate into all or some mesenchymal cells such as osteoblasts, chondroblasts, and lipoblasts.
- the medium according to the present invention can be suitably used for the proliferation of any stem cell, but preferably for culturing mesenchymal stem cells, ES cells or iPS cells, more preferably for culturing iPS cells.
- it can be used for culturing human iPS cells.
- human iPS cells include 253G1 strain (RIKEN Cell Bank No. HPS0002), 201B7 strain (RIKEN Cell Bank No. HPS0063), 409B2 strain (RIKEN Cell Bank No. HPS0076), 454E2 strain (RIKEN Cell Bank No. HPS0077), HiPS. -RIKEN-1A strain (RIKEN Cell Bank No.
- HPS0003 HiPS-RIKEN-2A strain (RIKEN Cell Bank No. HPS0009), HiPS-RIKEN-12A strain (RIKEN Cell Bank No. HPS0029), Nips-B2 strain (RIKEN Cell Bank No. HPS0223).
- Anchorage-dependent cell culture method The method for culturing anchorage-dependent cells according to the present invention is characterized by including a procedure for culturing anchorage-dependent cells in the absence of the scaffold in a medium containing MFG-E8. According to the culture medium of the present invention, it is possible to allow the anchorage-dependent cells to adhere to the substrate of the incubator and to grow (colony formation) even in the absence of the scaffold by the action of MFG-E8. That is, in the present invention, MFG-E8 can function as an adhesion promoter for anchorage-dependent cells.
- the incubator used in the culture method according to the present invention is not particularly limited, but a culture tank such as a flask, dish, petri dish, microwell plate, microslide, chamber slide, tube, tray, culture bag or tank, etc. Can be mentioned.
- the substrate of these incubators is not particularly limited, and examples thereof include glass, various plastics such as polypropylene and polystyrene, metals such as stainless steel, or combinations thereof.
- the substrate surface has been coated with a scaffold.
- Such scaffolds include collagen, gelatin, poly-L-lysine, poly-D-lysine, laminin, partial structures of laminin, fibronectin and mixtures thereof (eg, Matrigel) and lysed cell membrane preparations (Lancet, 2005, 365, p1636-1641).
- the culture method according to the present invention does not require coating of the substrate surface with such a scaffold, and can be applied to large-scale industrial culture.
- the anchorage-dependent cells may be dispersed cells at the start of culture.
- Dispersed cells include cells forming a small cell mass composed of several cells (typically about 2-50, 2-20, or 2-10).
- the culture density of the anchorage-dependent cells is not particularly limited as long as the density can achieve a desired effect such as an improvement in cell survival rate.
- Culture conditions such as temperature, CO 2 concentration, dissolved oxygen concentration, and pH can be appropriately set based on conventional techniques.
- the culture temperature is not particularly limited, but may be 30 to 40 ° C., preferably 37 ° C.
- the CO 2 concentration can be 1-10%, preferably 2-5%.
- the oxygen partial pressure can be 1-10%.
- the culture method according to the present invention can be applied to a method for producing a cell composition containing stem cells or a method for producing a cell composition containing differentiated cells from stem cells, particularly using stem cells as anchorage-dependent cells.
- the culture method of the present invention it is possible to grow stem cells by adhering stem cells to the base material of the incubator even in the absence of a scaffold. Therefore, by applying the culture method according to the present invention to a method for producing a cell composition containing stem cells or differentiated cells, it is not necessary to coat the surface of the base material with a scaffold, and heterogeneous animal-derived components or immunogenicity used as the scaffold. It is possible to prevent components and the like from being mixed into stem cells and differentiated cells.
- Specific steps of the method for producing a cell composition containing stem cells according to the present invention are as follows, for example.
- a step of culturing stem cells on feeder cells (B) A step of dissociating the stem cells from the feeder cells.
- Step (a) is a step of growing and maintaining stem cells in an undifferentiated state on feeder cells.
- Step (a) may be performed by applying a conventional method for culturing stem cells, and may be culturing in the presence of a scaffold and / or serum (or serum extract or the like).
- stromal cells such as fetal fibroblasts can be used (for example, Manipulating the Mouse Embryo A Laboratory, Second Edition, 1999, Cold Spring HarbourLaboratory Partnership; Press at Oxford University Press; Proc. Natl. Acad. Sci. USA, 1981, 78, 7634; Nature, 1981, 292, 154; J. Virol., 1969, 4, 549; Science, 1996, 272, 722; C . Ll Physiol, 1982,112,89;. See Nos. No. 2005/080554); International Publication No. 01/088100 issue.
- Step (b) is a step of dissociating stem cells from feeder cells
- step (c) is a method in which dissociated stem cells are allowed to adhere and proliferate in the absence of feeder cells and scaffolds by the culture method according to the present invention.
- Examples of the method for dissociating stem cells from the feeder cells in the step (b) include a chemical method using a reagent or an enzyme, a physical method using a membrane or a bead, or a combination thereof.
- the stem cells dissociated in the step (b) may be subjected to the step (a) again for passage.
- step (b) you may perform the process of culturing the cell obtained by the process (b) for a short period of time in the absence of a scaffold between the process (b) and the process (c).
- This additional step allows only the feeder cells to adhere to the substrate of the incubator and removes the feeder cells that are contaminated in the stem cells.
- serum when serum is used in step (a), the cells obtained in step (b) are washed with a serum-free medium or buffer between step (b) and step (c). You may perform a process.
- step (c) differentiation of the proliferated stem cells is induced.
- Stem cell differentiation can be induced by a method known per se. For example, by adding a differentiation inducer such as retinoic acid to the medium, it becomes possible to differentiate stem cells into nervous system cells and the like in the absence of a scaffold. Further, differentiation induction may be performed as a separate step after step (c), in which case the cell is treated with a differentiation-inducing agent in the presence or absence of MFG-E8, preferably in the presence in that step. do it.
- BMP inhibitors As the differentiation inducer, BMP inhibitors, Wnt inhibitors, Nodal inhibitors, retinoic acid and the like can be used.
- differentiation induction is performed by culturing mesenchymal stem cells in a differentiation induction medium (90% ⁇ MEM, 10% FBS, 2 mM L-glutamine, 0.1 ⁇ M dexamethasone). be able to.
- a differentiation induction medium for example, STEMdiff APEL Medium, STEMCELL
- the medium was added to 10 ng / ml BMP-4, 10 ng / ml Activin.
- the medium was replaced with 10 ng / ml VEGF, 150 ng / ml Dkk1, and after 8 days, the medium was replaced with 10 ng / ml VEGF, Cardiomyocytes with autonomous pulsation can be confirmed by exchanging them with those added with 150 ng / ml Dkk1, 10 ng / ml bFGF.
- Cell composition The cell composition containing stem cells and / or differentiated cells cultured in a medium containing MFG-E8 or a fragment of the protein in the absence of a scaffold according to the present invention is used for further stem cell culture or for regenerative medicine. Can be utilized for cell sources.
- the cell composition according to the present invention is obtained by the above-described production method, and may be a composition containing dispersed stem cells such as small cell clusters.
- the cell composition according to the present invention may contain MFG-E8 or a fragment of the protein derived from a medium containing MFG-E8 or a fragment of the protein used in step (c) of the production method described above, Other medium components may be included. Further, the cell composition may include feeder cells.
- the cell composition according to the present invention can be used, for example, for preservation, transportation, and passage of stem cells by cryopreservation.
- the cell composition according to the present invention further contains a medium component as described above, serum or an alternative thereof, or an organic solvent such as DMSO in addition to a known cell preservation solution. May be included.
- the concentration of serum or its substitute is not particularly limited, but may be 1 to 50% (v / v), preferably 5 to 20% (v / v).
- the concentration of the organic solvent is not particularly limited, but may be 0 to 50% (v / v), preferably 5 to 20% (v / v).
- the cell composition according to the present invention can be used as a medicine.
- known forms and compositions suitable for pharmaceuticals can be applied.
- a cell composition containing cardiomyocytes can be formed into a sheet and can be suitably transplanted into the heart for the treatment of heart disease.
- the cell composition according to the present invention can be applied to a patient by means such as transplantation, intravenous injection, subcutaneous injection, intra-articular injection, and intramuscular injection. It is preferable that the cell composition as a medicine does not contain serum from the viewpoint of preventing contamination with components derived from different animals.
- Example 1 Culture of human iPS cells in medium containing MFG-E8
- the effect of MFG-E8 when the anchorage-dependent cells were cultured in the absence of the scaffold was evaluated using human iPS cells.
- Human iPS cells (201B7, RIKEN Cell Bank No. HPS0063) were cultured (37 ° C, 5% CO 2 ) on feeder cells (mitomycin-treated mouse fetal fibroblasts). Passaging was performed every 3-4 days. Passage was performed by dissociating iPS cells from feeder cells using a dissociation solution, then dispersing them into small cell clusters (about 50 to 100 cells), and seeding on the feeder cells. The following were used for the culture solution and the dissociation solution.
- the small cell mass was seeded on a plate not coated with a scaffold (cell density: 1 ⁇ 10 5 cells / 0.65 cm 2 in a medium volume of 0.5 ml), and MFG-E8 (Recombinant Human MFG-E8, R & D
- the cells were cultured for 4 days in a maintenance culture solution (MFG-E8 2 ⁇ g / ml) containing Systems, Catalog # 2767-MF-050) or a maintenance culture solution containing no MFG-E8. After culture, the area of the formed colonies was measured.
- the MFG-E8 used here consists of an amino acid sequence obtained by adding a His tag sequence to the amino acid sequence (24th to 387th amino acid sequence) from which the signal sequence is deleted in SEQ ID NO: 1.
- FIG. 2 shows the results of the test conducted by changing the MFG-E8 addition concentration to 0, 0.5, 1, 2, 5 ⁇ g. At a concentration of 1 ⁇ g / ml or higher, cell engraftment and proliferation were significantly promoted.
- Example 2 Differentiation induction of human iPS cells by medium containing MFG-E8
- the differentiation ability of human iPS cells cultured in the absence of a scaffold using a medium containing MFG-E8 was evaluated.
- a small cell mass of iPS cells is seeded on a plate not coated with a scaffold, and does not contain a differentiation-inducing culture medium containing MFG-E8 (MFG-E8 1 ⁇ g / ml) or MFG-E8.
- the cells were cultured in a differentiation-inducing medium.
- a commercially available kit PSdif-Cardio Cardiomyocyte Differentiation Kit, Stem RD was used for the differentiation induction culture medium. This differentiation-inducing culture medium is serum-free. After 10 days of culture, the presence or absence of cardiomyocyte differentiation induction was confirmed with a microscope.
- MFG-E8 has the effect of promoting the adhesion of iPS cells in the absence of a scaffold and enabling cell survival and proliferation (colony formation), and further differentiation. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[1]MFG-E8(Milk fat globule-EGF factor 8)又は該タンパク質の断片を含む、足場依存性細胞の培地。
[2]前記足場依存性細胞が幹細胞である、[1]の培地。
[3]前記幹細胞が胚性幹細胞、誘導性多能性幹細胞又は間葉系幹細胞である、[2]の培地。
[4]前記足場依存性細胞がヒト由来である、[1]~[3]のいずれかの培地。
[5]無血清の培地である、[1]~[4]のいずれかの培地。
[8]前記足場依存性細胞が幹細胞である、[7]の培養方法。
[9]前記幹細胞が胚性幹細胞、誘導性多能性幹細胞又は間葉系幹細胞である、[8]の培養方法。
[10]前記足場依存性細胞がヒト由来である、[7]~[9]のいずれかの培養方法。
[11]前記培地が無血清の培地である、[7]~[10]のいずれかの培養方法。
[13](a)幹細胞をフィーダー細胞上で培養する工程と、
(b)前記フィーダー細胞から前記幹細胞を解離する工程と、
(c)MFG-E8又は該タンパク質の断片を含む培地で、フィーダー細胞非存在下、前記幹細胞を培養する工程と、を含む、幹細胞を含む細胞組成物の製造方法。
[14]前記工程(c)で用いる前記培地が無血清の培地である、[13]の製造方法。
[15]前記幹細胞が胚性幹細胞、誘導性多能性幹細胞又は間葉系幹細胞である、[12]~[14]のいずれかの製造方法。
[16]前記幹細胞がヒト由来である、[12]~[15]のいずれかの製造方法。
[18]前記幹細胞が胚性幹細胞、誘導性多能性幹細胞又は間葉系幹細胞である、[17]の製造方法。
[19]前記幹細胞がヒト由来である、[17]又は[18]の製造方法。
[20]前記培地が無血清の培地である、[17]~[19]のいずれかの製造方法。
[22]前記幹細胞が、胚性幹細胞、誘導性多能性幹細胞又は間葉系幹細胞である、[21]の細胞組成物。
[23]前記幹細胞が、ヒト由来である、[21]又は[22]の細胞組成物。
[24]前記培地が無血清の培地である、[21]~[23]のいずれかの細胞組成物。
[25]MFG-E8又は該タンパク質の断片を含む、[21]~[24]のいずれかの細胞組成物。
[MFG-E8]
本発明に係る足場依存性細胞の培地は、MFG-E8(Milk fat globule-EGF factor 8)又は該タンパク質の断片を含むことを特徴とする。
本発明に係る培地の組成は、MFG-E8を含む点を除いて、足場依存性細胞の培養のために従来用いられている培地と同様であってよい。このような培地としては、例えば、動物組織に由来する細胞の培養に用いられている培地が挙げられる。具体的には以下の培地を挙げることができる。
栄養因子としては、糖、アミノ酸、ビタミン、加水分解物または脂質などが挙げられる。
糖としては、グルコース、マンノースまたはフルクトースなどの中性糖;シアル酸などの酸性糖;アミノ糖;糖アルコールなどが挙げられ、1種または2種以上を組み合わせて用いられる。
アミノ酸としては、L-アラニン、L-アルギニン、L-アスパラギン、L-アスパラギン酸、L-システイン、L-グルタミン酸、L-グルタミン、グリシン、L-ヒスチジン、L-イソロイシン、L-ロイシン、L-リジン、L-メチオニン、L-フェニルアラニン、L-プロリン、L-セリン、L-スレオニン、L-トリプトファン、L-チロシンまたはL-バリンなどが挙げられ、1種または2種以上を組み合わせて用いられる。
ビタミンとしては、d-ビオチン、D-パントテン酸、コリン、葉酸、myo-イノシトール、ナイアシンアミド、ピロドキサール、リボフラビン、チアミン、シアノコバラミンまたはDL-α―トコフェロールなどが挙げられ、1種または2種以上を組み合わせて用いられる。
加水分解物としては、大豆、小麦、米、えんどう豆、とうもろこし、綿実、酵母抽出物などを加水分解したものが挙げられる。
脂質としては、コレステロール、リノール酸またはリノレイン酸などが挙げられる。
本発明において、「足場依存性細胞」は、生存及び/又は増殖のために接着していることを必要とし、非接着状態あるいは浮遊状態では生存及び/又は増殖が不能であるか又は著しく阻害される細胞を広く包含する。「足場依存性細胞」は、MFG-E8の存在下で足場なしで培養器の基材に接着して増殖可能である、動物組織に由来する細胞であれば特に制限されない。
幹細胞である足場依存性細胞の具体例としては、筋芽細胞、血管内皮細胞、骨芽細胞、脂肪細胞、筋細胞、心筋細胞、軟骨細胞等へ分化する間葉系幹細胞;ニューロンやグリア細胞へ分化する神経幹細胞;白血球、赤血球、血小板、肥満細胞、樹状細胞等へ分化する造血幹細胞又は骨髄幹細胞;スフェロイド状態から胚様体(EB体)と呼ばれる擬似的な胚の形成を経て様々な組織への分化・誘導のステップに進むことが知られている胚性幹細胞(Embryonic stem cell:ES細胞)や誘導性多能性幹細胞(induced pluripotent cell:iPS細胞)、始原生殖細胞に由来する胚性生殖(EG)細胞、精巣組織からのGS細胞の樹立培養過程で単離されるmultipotent germline stem(mGS)細胞、骨髄から単離されるmultipotent adult progenitor cell(MAPC)等の多能性幹細胞などが挙げられる。
幹細胞である足場依存性細胞のより具体的な例として、筋管に分化することが知られているC2C12株;脂肪細胞に分化することが知られている3T3-L1株;マウス胎児の大脳線条体由来のマウス神経幹細胞(MNSC);ラット胎児の中脳由来のラット神経幹細胞(RNSC);ラットの肝臓由来細胞株の3’-mRLh-2などが挙げられる。
多能性幹細胞とは、生体を構成する全ての組織や細胞へ分化し得る能力を有する細胞を意味する。
複能性幹細胞とは、全ての種類ではないが、複数種の組織や細胞へ分化し得る能力を有する細胞を意味する。
単能性幹細胞とは、特定の組織や細胞へ分化し得る能力を有する細胞を意味する。
[培養方法]
本発明に係る足場依存性細胞の培養方法は、MFG-E8を含む培地で、足場非存在下、足場依存性細胞を培養する手順を含むことを特徴とする。本発明に係る培地によれば、MFG-E8の作用によって、足場非存在下においても、足場依存性細胞を培養器の基材に接着させて増殖(コロニー形成)させることが可能である。すなわち、本発明において、MFG-E8は、足場依存性細胞の接着促進剤として機能し得るものである。
本発明に係る培養方法は、足場依存性細胞として特に幹細胞を用いることで、幹細胞を含む細胞組成物の製造方法あるいは幹細胞からの分化細胞を含む細胞組成物の製造方法に応用できる。本発明に係る培養方法によれば、足場非存在下においても、幹細胞を培養器の基材に接着させて増殖(コロニー形成)させることが可能である。従って、本発明に係る培養方法を幹細胞又は分化細胞を含む細胞組成物の製造方法に適用することで、足場による基材表面のコートが不要となり、足場として用いられる異種動物由来成分や免疫原性成分などが幹細胞や分化細胞に混入するのを防止できる。
(a)幹細胞をフィーダー細胞上で培養する工程。
(b)前記フィーダー細胞から前記幹細胞を解離する工程。
(c)MFG-E8又は該タンパク質の断片を含む培地で、フィーダー細胞非存在下、前記幹細胞を培養する工程。
本発明に係る幹細胞から分化細胞を含む細胞組成物を製造する方法では、上記工程(c)において、増殖した幹細胞の分化を誘導する。幹細胞の分化誘導は自体公知の手法によって行うことができる。例えばレチノイン酸などの分化誘導剤を培地に添加することにより、足場非存在下で、幹細胞を神経系細胞などに分化させることが可能となる。また、分化誘導を工程(c)の後に別途の工程として行ってもよく、その場合には当該工程においてMFG-E8の存在下又は非存在下、好ましくは存在下で細胞に分化誘導剤を処理すればよい。
また、心筋細胞の分化誘導プロセスでは、培地(例えば、STEMdiff APEL Medium、STEMCELL社)に0.5ng/ml BMP-4を添加し、1日後、培地を10ng/ml BMP-4、10ng/ml Activin A、5ng/ml bFGFを添加した物に交換し、4日目後、培地を10ng/ml VEGF、150ng/ml Dkk1を添加した物に交換し、8日目後、培地を10ng/ml VEGF、150ng/ml Dkk1、10ng/ml bFGFを添加した物に交換することで自律的な拍動を伴う心筋細胞を確認できる。
本発明に係る、足場非存在下、MFG-E8又は該タンパク質の断片を含む培地で培養された幹細胞及び/又は分化細胞を含む細胞組成物は、さらなる幹細胞の培養のため、あるいは再生医療用の細胞ソースのために利用され得る。
足場依存性細胞を足場非存在下で培養した場合におけるMFG-E8の効果を、ヒトiPS細胞を用いて評価した。
ヒトiPS細胞(201B7、理研セルバンクNo.HPS0063)を、フィーダー細胞(マイトマイシン処理マウス胎児線維芽細胞)上で培養(37℃、5%CO2)した。継代は、3~4日毎に行った。継代は、解離液を用いてiPS細胞をフィーダー細胞から解離した後、小細胞塊(約50~100個)に分散し、フィーダー細胞上に播種することにより行った。培養液及び解離液には以下を用いた。
培養液:
D-MEMF12(SIGMA社)
Knockout Serum Replacement(Life Technologies社) 20%
MEM NON-ESSENTIAL AMINO ACID[×100](SIGMA社 製品番号:M7145) 1%
L-グルタミン酸 2.0mM
2-メルカプトエタノール 80μM
解離液:
ダルベッコリン酸緩衝生理食塩水(SIGMA社、製品番号:D5652)
トリプシン 0.25%
コラゲナーゼIV 1mg/ml
CaCl2 1mM
iPS細胞をフィーダー細胞から小細胞塊として解離した。小細胞塊中に混入するフィーダー細胞を除去するために、小細胞塊を足場(ゼラチン)がコートされたプレートに移し、維持培養液(Essential-8,Life Technologies社)中で1時間培養してフィーダー細胞をプレートに吸着させた。なお、この維持培養液は、無血清である。その後、小細胞塊を足場がコートされていないプレートに播種し(細胞密度:1×105個/0.65cm2、培地容量0.5ml中)、MFG-E8(Recombinant Human MFG-E8、R&D Systems社、Catalog #2767-MF-050)を含む維持培養液(MFG-E8 2μg/ml)又はMFG-E8を含まない維持培養液で4日間培養した。培養後、形成されたコロニーの面積を計測した。なお、ここで用いたMFG-E8は、配列番号1においてシグナル配列を欠失させたアミノ酸配列(24番目から387番目のアミノ酸配列)にHisタグ配列を付加したアミノ酸配列からなる。
結果を図1に示す。MFG-E8を含まない培地では、コロニーはほとんど認められなかったが、MFG-E8を添加した培地では、多数のコロニーが認められた。MFG-E8添加培地で生育したコロニーは、未分化胚性幹細胞のマーカーであるアルカリフォスファターゼを発現していた。これらの結果から、MFG-E8が、足場非存在下におけるiPS細胞の接着を促進し、細胞の生存と増殖(コロニー形成)を可能とする効果を有することが明らかとなった。また、MFG-E8添加濃度を0,0.5,1,2,5μgに変更して試験を行った結果を図2に示す。1μg/ml以上の濃度では、細胞の生着と増殖が顕著に促進された。
MFG-E8含有培地を用いて足場非存在下で培養したヒトiPS細胞の分化能を評価した。
Claims (25)
- MFG-E8(Milk fat globule-EGF factor 8)又は該タンパク質の断片を含む、足場依存性細胞の培地。
- 前記足場依存性細胞が幹細胞である、請求項1記載の培地。
- 前記幹細胞が胚性幹細胞、誘導性多能性幹細胞又は間葉系幹細胞である、請求項2記載の培地。
- 前記足場依存性細胞がヒト由来である、請求項1~3のいずれか一項に記載の培地。
- 無血清の培地である、請求項1~4のいずれか一項に記載の培地。
- MFG-E8又は該タンパク質の断片を含む、足場依存性細胞の接着促進剤。
- MFG-E8又は該タンパク質の断片を含む培地で、足場非存在下、足場依存性細胞を培養する手順を含む、足場依存性細胞の培養方法。
- 前記足場依存性細胞が幹細胞である、請求項7記載の培養方法。
- 前記幹細胞が胚性幹細胞、誘導性多能性幹細胞又は間葉系幹細胞である、請求項8記載の培養方法。
- 前記足場依存性細胞がヒト由来である、請求項7~9のいずれか一項に記載の培養方法。
- 前記培地が無血清の培地である、請求項7~10のいずれか一項に記載の培養方法。
- MFG-E8又は該タンパク質の断片を含む培地で、足場非存在下、幹細胞を培養する工程を含む、幹細胞を含む細胞組成物の製造方法。
- (a)幹細胞をフィーダー細胞上で培養する工程と、
(b)前記フィーダー細胞から前記幹細胞を解離する工程と、
(c)MFG-E8又は該タンパク質の断片を含む培地で、フィーダー細胞非存在下、前記幹細胞を培養する工程と、を含む、幹細胞を含む細胞組成物の製造方法。 - 前記工程(c)で用いる前記培地が無血清の培地である、請求項13記載の製造方法。
- 前記幹細胞が胚性幹細胞、誘導性多能性幹細胞又は間葉系幹細胞である、請求項12~14のいずれか一項に記載の製造方法。
- 前記幹細胞がヒト由来である、請求項12~15のいずれか一項に記載の製造方法。
- MFG-E8又は該タンパク質の断片を含む培地で、足場非存在下、幹細胞の分化を誘導する工程を含む、幹細胞からの分化細胞を含む細胞組成物の製造方法。
- 前記幹細胞が胚性幹細胞、誘導性多能性幹細胞又は間葉系幹細胞である、請求項17の製造方法。
- 前記幹細胞がヒト由来である、請求項17又は請求項18記載の製造方法。
- 前記培地が無血清の培地である、請求項17~19のいずれか一項に記載の製造方法。
- 足場非存在下、MFG-E8又は該タンパク質の断片を含む培地で培養された、幹細胞及び/又は幹細胞から誘導された分化細胞を含む細胞組成物。
- 前記幹細胞が、胚性幹細胞、誘導性多能性幹細胞又は間葉系幹細胞である、請求項21記載の細胞組成物。
- 前記幹細胞が、ヒト由来である、請求項21又は請求項22記載の細胞組成物。
- 前記培地が無血清の培地である、請求項21~23のいずれか一項に記載の細胞組成物。
- MFG-E8又は該タンパク質の断片を含む、請求項21~24のいずれか一項に記載の細胞組成物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/313,861 US20170198262A1 (en) | 2014-05-28 | 2015-05-28 | Culture medium and culturing method for anchorage-dependent cells, cell composition including stem cells and/or differentiated cells derived from stem cells, and production method for cell composition |
JP2016523155A JPWO2015182140A1 (ja) | 2014-05-28 | 2015-05-28 | 足場依存性細胞の培地及び培養方法、並びに幹細胞及び/又は幹細胞から誘導された分化細胞を含む細胞組成物及びその製造方法 |
EP15800288.1A EP3150700A4 (en) | 2014-05-28 | 2015-05-28 | Culture medium and culturing method for anchorage-dependent cells, cell composition including stem cells and/or differentiated cells derived from stem cells, and production method for cell composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014110450 | 2014-05-28 | ||
JP2014-110450 | 2014-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015182140A1 true WO2015182140A1 (ja) | 2015-12-03 |
Family
ID=54698486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/002694 WO2015182140A1 (ja) | 2014-05-28 | 2015-05-28 | 足場依存性細胞の培地及び培養方法、並びに幹細胞及び/又は幹細胞から誘導された分化細胞を含む細胞組成物及びその製造方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20170198262A1 (ja) |
EP (1) | EP3150700A4 (ja) |
JP (1) | JPWO2015182140A1 (ja) |
WO (1) | WO2015182140A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018181342A1 (ja) * | 2017-03-28 | 2018-10-04 | 味の素株式会社 | 未分化維持培地添加剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020067502A1 (ja) * | 2018-09-28 | 2020-04-02 | 味の素株式会社 | 動物細胞の培養用添加物、培養用培地および培養方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130060670A (ko) * | 2011-11-30 | 2013-06-10 | 고려대학교 산학협력단 | Milk fat globule ― EGF factor 8(MFGE8)을 이용한 간 재생 및 간 질환 개선 용도 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100883565B1 (ko) * | 2007-02-14 | 2009-02-13 | (주)프로스테믹스 | 지방 줄기세포의 조직 재생 능력을 최적화한 조건 배지를 함유한 조직 재생용 주사제 첨가제 |
-
2015
- 2015-05-28 US US15/313,861 patent/US20170198262A1/en not_active Abandoned
- 2015-05-28 JP JP2016523155A patent/JPWO2015182140A1/ja active Pending
- 2015-05-28 EP EP15800288.1A patent/EP3150700A4/en not_active Withdrawn
- 2015-05-28 WO PCT/JP2015/002694 patent/WO2015182140A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130060670A (ko) * | 2011-11-30 | 2013-06-10 | 고려대학교 산학협력단 | Milk fat globule ― EGF factor 8(MFGE8)을 이용한 간 재생 및 간 질환 개선 용도 |
Non-Patent Citations (8)
Title |
---|
BOCCA, S. ET AL.: "Milk fat globule epithelial growth factor 8 (MFG-E8) regulates human endometrial endothelial cell adhesion and proliferation", FERTILITY AND STERILITY, vol. 94, no. 4, 2010, pages S215 - S216, XP027250687 * |
BU, H.F. ET AL.: "Milk fat globule-EGF factor 8/ lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 117, no. 12, 2007, pages 3673 - 3683, XP055241458 * |
CHEYUO, C. ET AL.: "MFG-E8 regulates neural stem cell proliferation and migration via integrin AVB3/PPARy/cyclin D2/netrin-1 pathway", SHOCK, vol. 39, no. Supplement. 2, 2013, pages 15, XP055241380 * |
HAILE, Y. ET AL.: "The effect of modified polysialic acid based hydrogels on the adhesion and viability of primary neurons and glial cells", BIOMATERIALS, vol. 29, 2008, pages 1880 - 1891, XP022499086 * |
MOTEGI, S. ET AL. * |
See also references of EP3150700A4 * |
TAKAHASHI, H. ET AL.: "Isolation and Culture of Bovine Endometrial Epithelial Cells in a Serum- Free Culture System", JOURNAL OF REPRODUCTION AND DEVELOPMENT, vol. 47, no. 3, 2001, pages 181 - 187, XP055241377 * |
UCHIYAMA, A. ET AL.: "The regulation of skin wound healing by MFG-E8", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 133, no. Supplement 1, 2013, pages s251, XP055241456 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018181342A1 (ja) * | 2017-03-28 | 2018-10-04 | 味の素株式会社 | 未分化維持培地添加剤 |
JPWO2018181342A1 (ja) * | 2017-03-28 | 2020-02-20 | 味の素株式会社 | 未分化維持培地添加剤 |
JP7181534B2 (ja) | 2017-03-28 | 2022-12-01 | 味の素株式会社 | 未分化維持培地添加剤 |
JP7445268B2 (ja) | 2017-03-28 | 2024-03-07 | 味の素株式会社 | 未分化維持培地添加剤 |
Also Published As
Publication number | Publication date |
---|---|
EP3150700A1 (en) | 2017-04-05 |
US20170198262A1 (en) | 2017-07-13 |
JPWO2015182140A1 (ja) | 2017-04-20 |
EP3150700A4 (en) | 2017-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11421203B2 (en) | Method of producing human retinal pigment epithelial cells | |
US11492600B2 (en) | Methods and products for transfection | |
EP3119881B1 (en) | Production of midbrain dopaminergic neurons and methods for the use thereof | |
US10829733B2 (en) | Composition and method for enabling proliferation of pluripotent human stem cells | |
JP6744084B2 (ja) | 幹細胞由来の分化細胞用培地、幹細胞からの分化細胞の製造及び該分化細胞を含む細胞医薬組成物の製造のための方法 | |
EP2828380B1 (en) | Methods and media for differentiating eye cells | |
KR101861171B1 (ko) | 투석된 혈청이 있는 심근세포 배지 | |
WO2011110886A1 (en) | Composition and method for enabling proliferation of pluripotent human stem cells | |
WO2021106765A1 (ja) | ナイーブ型多能性幹細胞からの栄養外胚葉誘導方法 | |
KR20170132281A (ko) | 사람 혈청 알부민을 포함하는 신경 줄기세포 증식 배지 | |
WO2023127824A1 (ja) | 神経堤細胞の培養方法及び製造方法 | |
CA3026199A1 (en) | Differentiation of pluripotent stem cells into corneal cells | |
WO2015182140A1 (ja) | 足場依存性細胞の培地及び培養方法、並びに幹細胞及び/又は幹細胞から誘導された分化細胞を含む細胞組成物及びその製造方法 | |
WO2016187451A1 (en) | Multi-pathway induction of stem cell differentiation with rna | |
WO2015008275A1 (en) | Methods for large scale generation of stem cells | |
WO2017082296A1 (ja) | 軟骨組織塊及びその製造方法、並びに幹細胞から軟骨組織塊を誘導するための培地 | |
Kunova et al. | Development of humanized culture medium with plant-derived serum replacement for human pluripotent stem cells | |
KR20180132787A (ko) | 신경 분화능을 항진시키는 신경 줄기 세포용 배지 | |
WO2017082294A1 (ja) | 幹細胞の培養用培地、増殖促進剤及び培養方法、並びに幹細胞を含む細胞組成物及びその製造方法 | |
JP7328688B2 (ja) | 副甲状腺細胞の作製方法 | |
EP4092046A1 (en) | Cell culture medium composition | |
WO2017082295A1 (ja) | 軟骨組織塊及びその製造方法、並びに幹細胞から軟骨組織塊を誘導するための培地 | |
WO2016190288A1 (ja) | 幹細胞培養用の培地、増殖促進剤及び培養方法 | |
WO2023037544A1 (ja) | 多能性幹細胞の製造方法 | |
JP2020129970A (ja) | 多能性幹細胞を培養するための組成物及び方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15800288 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016523155 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15313861 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015800288 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015800288 Country of ref document: EP |